• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于理解缺氧激活前药抗癌活性的新型模型系统。

A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.

机构信息

Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China.

College of Medicine, Nankai University, Tianjin 300071, China.

出版信息

Mol Pharm. 2020 Jun 1;17(6):2072-2082. doi: 10.1021/acs.molpharmaceut.0c00232. Epub 2020 May 11.

DOI:10.1021/acs.molpharmaceut.0c00232
PMID:32352301
Abstract

Reports on the comprehensive factors for design considerations of hypoxia-activated prodrugs (HAPs) are rare. We introduced a new model system composed of a series of highly water-soluble HAPs, providing a platform to comprehensively understand the interaction between HAPs and hypoxic biosystems. Specifically, four kinds of new HAPs were designed and synthesized, containing the same biologically active moiety but masked by different bioreductive groups. Our results demonstrated that the activity of the prodrugs was strongly dependent on not only the molecular structure but also the hypoxic tumor microenvironment. We found the presence of a direct linear relationship between cytotoxicity of the HAPs and the reduction potential of whole molecule/oxygen concentration/reductase expression. Moreover, limited blood vasculature in hypoxic regions was also a critical barrier for effective activation of the HAPs. This study offers a comprehensive insight into understanding the design factors required for HAPs.

摘要

关于缺氧激活前药(HAPs)设计考虑因素的综合报告很少。我们引入了一个由一系列高水溶性 HAPs 组成的新模型系统,为全面了解 HAPs 与缺氧生物系统之间的相互作用提供了一个平台。具体来说,设计并合成了四种新型 HAPs,它们含有相同的生物活性部分,但被不同的生物还原基团掩蔽。我们的结果表明,前药的活性不仅强烈依赖于分子结构,还依赖于缺氧肿瘤微环境。我们发现 HAPs 的细胞毒性与整个分子/氧浓度/还原酶表达的还原电位之间存在直接的线性关系。此外,缺氧区域有限的血管系统也是有效激活 HAPs 的一个关键障碍。这项研究为理解 HAPs 所需的设计因素提供了全面的认识。

相似文献

1
A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.用于理解缺氧激活前药抗癌活性的新型模型系统。
Mol Pharm. 2020 Jun 1;17(6):2072-2082. doi: 10.1021/acs.molpharmaceut.0c00232. Epub 2020 May 11.
2
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.使用缺氧激活前药靶向肿瘤的缺氧部分。
Cancer Chemother Pharmacol. 2016 Mar;77(3):441-57. doi: 10.1007/s00280-015-2920-7. Epub 2016 Jan 25.
3
Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.研究性缺氧激活前药:展望未来发展。
Curr Drug Targets. 2019;20(6):668-678. doi: 10.2174/1389450120666181123122406.
4
Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.利用缺氧激活前药预防实体瘤中的耐药性。
PLoS Comput Biol. 2016 Aug 25;12(8):e1005077. doi: 10.1371/journal.pcbi.1005077. eCollection 2016 Aug.
5
Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers.精准脑胶质瘤治疗:缺氧激活前药经纳米光敏剂增敏。
Biomaterials. 2022 Oct;289:121770. doi: 10.1016/j.biomaterials.2022.121770. Epub 2022 Sep 1.
6
Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.用计算方法评估肿瘤对缺氧靶向前药的治疗反应。
Math Biosci Eng. 2022 Aug 1;19(11):10941-10962. doi: 10.3934/mbe.2022511.
7
Significance of Specific Oxidoreductases in the Design of Hypoxia-Activated Prodrugs and Fluorescent Turn off-on Probes for Hypoxia Imaging.特定氧化还原酶在缺氧激活前药设计及用于缺氧成像的荧光开-关探针中的意义。
Cancers (Basel). 2022 May 29;14(11):2686. doi: 10.3390/cancers14112686.
8
Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.缺氧激活前药与放射治疗联合应用的临床进展
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1183-1196. doi: 10.1016/j.ijrobp.2017.03.024. Epub 2017 Mar 22.
9
Noncovalent Theranostic Prodrug for Hypoxia-Activated Drug Delivery and Real-Time Tracking.用于缺氧激活药物递送和实时跟踪的非共价治疗前药
Anal Chem. 2021 Nov 16;93(45):15080-15087. doi: 10.1021/acs.analchem.1c03153. Epub 2021 Nov 7.
10
Hypoxia Activated Prodrugs: Factors Influencing Design and Development.缺氧激活前药:影响设计与开发的因素
Curr Med Chem. 2015;22(37):4313-25. doi: 10.2174/0929867322666151021111016.

引用本文的文献

1
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy.用于癌症治疗的硝基芳香族低氧激活前药
Pharmaceuticals (Basel). 2022 Feb 2;15(2):187. doi: 10.3390/ph15020187.